<unk> , marketed as Priligy, among others, is a medication used for the treatment of premature ejaculation (PE) in men 18–64 years old.<unk>  works by inhibiting the serotonin transporter, increasing serotonin's action at the postsynaptic cleft, and as a consequence promoting ejaculatory delay. As a member of the selective serotonin reuptake inhibitor (SSRI) family,<unk>  was initially created as an antidepressant. However, unlike other SSRIs,<unk>  is absorbed and eliminated rapidly in the body. Its fast-acting property makes it suitable for the treatment of PE, but not as an antidepressant. Originally created by Eli Lilly pharmaceutical company,<unk>  was sold to Johnson & Johnson in 2003 and submitted as a New Drug Application to the Food and Drug Administration (FDA) for the treatment of PE in 2004.<unk>  is sold in several European and Asian countries, and in Mexico. In the US,<unk>  has been in phase III development. In May 2012, USA-based Furiex Pharmaceuticals reached an agreement with ALZA Corp and Janssen Pharmaceutica to market<unk>  in the USA, Japan, and Canada, while selling the rights to market the drug in Europe, most of Asia, Africa, Latin America, and the Middle East to Menarini.
Dapoxetine
Atomoxetine
Duloxetine
Edivoxetine
Vortioxetine
Fluoxetine
Nabilone
Guanfacine